GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Other Current Assets

Cadence Pharmaceuticals, (FRA:QEW) Other Current Assets : €1.85 Mil (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Other Current Assets?

Cadence Pharmaceuticals,'s other current assets for the quarter that ended in Dec. 2013 was €1.85 Mil.

Cadence Pharmaceuticals,'s quarterly other current assets declined from Jun. 2013 (€2.31 Mil) to Sep. 2013 (€1.39 Mil) but then increased from Sep. 2013 (€1.39 Mil) to Dec. 2013 (€1.85Mil).

Cadence Pharmaceuticals,'s annual other current assets increased from Dec. 2011 (€1.22 Mil) to Dec. 2012 (€1.37 Mil) increased from Dec. 2012 (€1.37 Mil) to Dec. 2013 (€1.85 Mil).


Cadence Pharmaceuticals, Other Current Assets Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Other Current Assets Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.07 1.22 1.37 1.85

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 2.07 2.31 1.39 1.85

Cadence Pharmaceuticals, Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Cadence Pharmaceuticals, Other Current Assets Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines